PRI-002

N/A

Report date: 2024/01/15 11:18:46
NME

Base Information

Drug NamePRI-002
Drug Alias NameContraloidContraloid AcetateRD-2PRI-002
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsCognitive DysfunctionAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaPolandNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPriavoidPRInnovation GmbH
China Registration ClassN/A

Develop Information

Active CompaniesPRInnovation GmbHPriavoidCharite University, Berlin, Germany +[4] 
Inactive CompaniesMedical University Of Vienna
Active IndicationsCognitive DysfunctionAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A